Introduction {#s1}
============

Epigenetic information is heritable but not encoded in the DNA sequence [@pone.0001731-Egger1]. DNA methylation is an important epigenetic mechanism for pretranscriptional control, and plays an essential role in regulating genes\' expression and maintaining cellular function [@pone.0001731-Weber1]. DNA methylation is restricted to CpG dinucleotides in mammals, which commonly locate on transposable elements and promoters [@pone.0001731-Jeltsch1]. Numerous studies have shown that changes in DNA methylation patterns may contribute to neoplastic disease or cancer susceptibility [@pone.0001731-Scholzova1], [@pone.0001731-Shames1], [@pone.0001731-Shi1], [@pone.0001731-Widschwendter1], [@pone.0001731-Davis1], [@pone.0001731-Davis2], [@pone.0001731-Jelinic1], [@pone.0001731-Davis3]. The nonrandom occurrence and observed patterns of CpG-rich methylation events further suggest that gene-specific methylation provides potentially useful markers for molecular diagnostics and detection of neoplastic disease risks [@pone.0001731-Waterland1].

Neoplastic diseases are defined as any malignant growth or tumor resulted from abnormal or uncontrolled cell division. It may spread to other parts of the body through the lymphatic system or the blood stream. Neoplastic diseases are a serious concern to the poultry industry due to the cost of routine vaccination against an herpesvirus that induces Marek\'s disease lymphomas [@pone.0001731-Nair1] and the eradication of avian leukosis viruses from breeders [@pone.0001731-Fadly1]. Avian leukosis viruses (ALVs) are associated with a variety of tumors including lymphoid leukosis, myeloblastosis, erythroblastosis, osteopetrosis, myxosarcomas and fibrosarcomas. The ALVs are retroviruses and have six subgroups [@pone.0001731-Fadly1]. Among the avian retroviruses, *ALVE* is the unique endogenous virus (*ev*). The other five ALVs, including ALVA, ALVB, ALVC, ALVD and ALVJ, are exogenous viruses [@pone.0001731-Crittenden1], [@pone.0001731-Crittenden2]. *ALVE* is inherited as LTR (long terminal repeat) retrotransposons [@pone.0001731-Crittenden3], [@pone.0001731-Cullen1], [@pone.0001731-Crittenden4], [@pone.0001731-Borisenko1].

Chicken *ALVE* loci are present in the genome of most chickens and can be inherited as normal cellular genes [@pone.0001731-Conklin1]. Since *ALVE* were first identified in chicken cells as ALV group-specific antigens [@pone.0001731-Crittenden5], more than 22 *ALVE* loci have been defined in the genome of White Leghorn chickens (Crittenden, 1991). Some *ALVE* are actively transcribed from their inherited chromosomal locations, whereas others (*e.g*., *ALVE1*) are silent [@pone.0001731-Baker1]. *ALVEs* relevant to this study are *ALVE1*, *ALVE2* and *ALVE3*. *ALVE1* is located on chromosome 1, *ALVE2* is located on chromosome 2, and *ALVE3* is found on one of the many microchromosomes. Inbred line 6~3~ has one copy of *ALVE1* and *ALVE3* whereas line 7~2~ has one copy of *ALVE1* and *ALVE2* [@pone.0001731-Crittenden6]. The cellular receptor of each ALV subgroup is encoded by a tumor virus locus (*TV*), which mediates viral entry. *TVA* and *TVC* encode the cellular receptors for ALV of subgroup A and C, respectively, *TVB* is the cellular receptor gene for ALV of subgroup B, D and E [@pone.0001731-Elleder1], [@pone.0001731-Bates1].

The highly inbred line 6~3~ at the Avian Disease and Oncology Laboratory (ADOL) are resistant to Marek\'s disease (MD) tumors but susceptible to both Marek\'s disease virus (MDV) and avian leukosis viruses (ALV), whereas the highly inbred line 7~2~ chickens are resistant to ALV (subgroup A, B, D, and E) but susceptible to both MDV and MD tumors [@pone.0001731-Bacon1]. Therefore, these inbred lines constitute unique models for epigenetic research by making it possible to explore the mechanisms of resistance and susceptibility to neoplastic diseases [@pone.0001731-Bacon1], [@pone.0001731-Bacon2] .

In this research, we hypothesize that the methylation status of *ALVE* and *TVB* genes are associated with resistance and susceptibility to neoplastic disease. To examine the hypothesis, we did DNA methylation analysis by pyrosequencing, which was recently developed as a quantitative technique to detect changes in methylation patterns [@pone.0001731-Colella1], [@pone.0001731-Tost1]. This technique is advantageous for analyzing and quantifying the degree of methylation of multiple CpG sites in one reaction. In order to advance our understanding of genetic mechanisms and to develop a better strategy for disease prevention, we have investigated epigenetic differences in methylation patterns between lines 6~3~ and 7~2~, as well as six recombinant congenic strains (RCSs) that developed from background inbred line 6~3~ and donor line 7~2~. This unique model system provides a way to elucidate mechanisms that may induce susceptibility or enhance resistance to viral induced tumors.

We first analyzed variations of DNA methylation patterns in four consensus regions among *ALVE1*, *2* and *3*, including one region unique for *ALVE1* as well as the promoter region of the *TVB* gene in ALV-susceptible line 6~3~and ALV-resistant line 7~2~using pyrosequencing. Next, we investigated line-specific gene expression for *ALVEs* and *TVB* with real-time RT-PCR. Subsequently, we characterized potential differences in *ALVEs PPT* (polypurine tract) region and *U3* region of 3′*LTR* between the lines by DNA sequencing. The effects of *ALVEs* and *TVB* methylation status on the tumor susceptible and resistant lines and six recombinant congenic strains are discussed. Our results suggest that variation in methylation patterns of *ALVE, TVB* and variations in the *PPT* region may be factors that contribute to viral induced tumors in chicken.

Results {#s2}
=======

Profiling DNA methylation patterns of *ALVEs* in two inbred chicken lines {#s2a}
-------------------------------------------------------------------------

The whole *ALVE1* is a CpG island that including 813 CpG sites within 7.5 kp based on the BLAT with UCSC Genomic Browser ([Figure 1](#pone-0001731-g001){ref-type="fig"}). To determine the DNA methylation levels of *ALVEs*, we selected four conserved regions among *ALVE1, 2* and *3* that cover the *gag* gene, *PPT* region and *U3* regions of 5′ and 3′ *LTR*, then quantitative evaluated the methylation differences between inbred chicken line 6~3~ and line 7~2~ using pyrosequencing method in four different tissues (blood, liver, spleen and hypothalamus) ([Figure 1](#pone-0001731-g001){ref-type="fig"}). [Figure 2A, 2B and 2C](#pone-0001731-g002){ref-type="fig"} show the typical methylation pyrograms for the six CpG sites in *ALVE* region 1 (*p19* matrix protein in *gag* gene), the five CpG sites in *ALVE* region 2 (Direction Repeat Sequence, DRS, adjacent to 3′ *LTR* of *ALVE*), and the four CpG sites in *ALVE* region 3/4 (*U3* region in 5′ and 3′ *LTR* of *ALVE*) in blood of line 7~2~ and line 6~3~, respectively. The averages from five individuals showed that hypermethylated CpG sites were identified in blood of line 7~2~ , 85.56±2.66% for *ALVE* region 1 and 91.86±1.63% for *ALVE* region 2, whereas the same regions are hypomethylated (10.05±2.56%) and hemimethylated (46.16±3.41%) in the line 6~3~ ([Figure 2](#pone-0001731-g002){ref-type="fig"}). The measurements using pyrosequencing technique for each conserved region of *ALVE* were proved to be highly reproducible between biological replicates. Moreover, the methylation percentages of region 2 in *ALVE* from bisulfite cloning and sequencing methods were very comparable to that from pyrosequencing as shown in [Figure S2](#pone.0001731.s005){ref-type="supplementary-material"}, which validated the pyrosequencing data.

![Four conserved regions (region1∼4) on *ALVEs* and one unique region (region5) of *ALVE1* for pyrosequencing and real-time RT-PCR.\
5′LTR: 5′ long terminal repeat; U3: U3 region in LTR; R: R region in LTR; U5: U5 region in LTR; *gag*: *gag* gene; pol: *pol* gene; *env*: env gene; PPT: polypurine tract; 3′LTR: 3′ long terminal repeat of *ALVE*. *PPT-U3* region: combined *PPT* and *U3* regions for real-time RT-PCR. Green arrow shows the CpG islands that including 813 CpG sites within 7525 bp of *ALVE1* (Blat result from UCSC Genome Browser website).](pone.0001731.g001){#pone-0001731-g001}

![Representative pyrograms for each gene region in line 7~2~ and 6~3~.\
The percentage on each CpG site is the methylation percentage of ^m^C/(^m^C+C) on this site. ^m^C: methylated cytosine, C: unmethylated cytosine. The sequence above the peak is the sequence to assay. The x axes are the dispensation nucleotides to the sequencing reaction based on the assayed sequences. The y axes show light emission obtained as relative light units. A: *ALVE* region1 in blood (the mean value of methylation percentage is 81.8±2.9 in line 7~2~ and 13.2±1.2 in 6~3~); B: *ALVE* region2 in blood (the mean value of methylation percentage is 85±1.6 in line 7~2~ and 47.6±2.3 in 6~3~); C: *ALVE* region3/4 in blood (the mean value of methylation percentage is 80.8±4.8 in line 7~2~ and 68.8±6.7 in 6~3~); D: Promoter region of *TVB* in Hypothalamus (the mean value of methylation percentage is 45.7±14.8 in line 7~2~ and 37.0±14.1 in 6~3~).](pone.0001731.g002){#pone-0001731-g002}

In order to compare the DNA methylation differences of the conserved *ALVE* regions between line 7~2~ and line 6~3~ in spleen, liver, hypothalamus and blood, point-wise comparison method was carried out at each CpG site. As depicted in [Figure 3A and 3B](#pone-0001731-g003){ref-type="fig"} and [Table S1](#pone.0001731.s001){ref-type="supplementary-material"} and [S2](#pone.0001731.s002){ref-type="supplementary-material"}, we found that the methylation contents for each CpG site in *ALVE* region 1 and *ALVE* region 2 were very significantly higher in the four tissues in line 7~2~ than in line 6~3~ (*P*\<0.0001), except for *ALVE* region 2 in hypothalamus (*P*\<0.01). Hypermethylated patterns (methylation level \>60%) in *ALVEs* region 1 and 2 existed in line 7~2~, while line 6~3~ showed a hypomethylated pattern (methylation level \<30%) in *ALVEs* region 1 and a hemimethylated pattern (30%\< methylation level \<60%) in *ALVEs* region 2 except for a hypermethylated pattern in the hypothalamus. As for *ALVEs* region 3/4, although line 7~2~ and line 6~3~had a hypermethylated status in the four tissues, the DNA methylation level was significantly higher in line 7~2~ than in line 6~3~ in spleen (*P*\<0.01), hypothalamus (*P*\<0.01) and blood (*P*\<0.0001), but not in the liver (*P*\>0.5) ([Figure 3C](#pone-0001731-g003){ref-type="fig"} and [Table S3](#pone.0001731.s003){ref-type="supplementary-material"}).

![Results of quantitative DNA methylation analysis on conserved regions of *ALVEs* in spleen, liver, hypothalamus and blood.\
\*\**P*\<0.0001. \**P*\<0.01. A: Methylation levels for each CpG site in the *ALVE* region1. B: Methylation levels for each CpG site in the *ALVE* region2. C: Methylation levels for each CpG site in the *ALVE* region3 and 4. *n* = 5 for each line.](pone.0001731.g003){#pone-0001731-g003}

mRNA expression level of *ALVEs* {#s2b}
--------------------------------

There is a typical retroviral polypurine tract (*PPT*) adjacent to the *U3* region of the 3′ *LTR* in *ALVEs* ([Figure 1](#pone-0001731-g001){ref-type="fig"}). The *PPT* is a short RNA sequence that generally serves as a primer for plus-strand DNA synthesis during reverse transcription and initiation of DNA synthesis, then, the *PPT* primer is accurately removed from nascent DNA to create a double-stranded, integration-competent DNA provirus. Due to the importance of *PPT-U3* region, real-time quantitative RT-PCR on the *PPT-U3* region was used to examine the transcriptional activation level of *ALVEs*. As shown in [Figure 4A and 4B](#pone-0001731-g004){ref-type="fig"}, RNA expression levels of the *PPT-U3* region were significantly higher in line 6~3~ than in line 7~2~ in the spleen (*P*\<0.01), liver and hypothalamus (*P*\<0.0001). There was no significant difference among tissues within either line (*P*\>0.05).

![mRNA expression of *PPT- U3* region on 3′ *ALVE* in line 6~3~ and line 7~2~.\
A: RT-PCR results. B: Real-time quantitative RT-PCR analysis. *n* = 5 for each line. \**P* = 0.01; \*\* *P*\<0.0001.](pone.0001731.g004){#pone-0001731-g004}

Variation of Polypurine Tract (*PPT*) Site among *ALVEs* {#s2c}
--------------------------------------------------------

To further ascertain the genetic background of the two inbred lines and explore the potential mechanisms of methylation content influencing the mRNA expression levels, we did sequencing analysis for the *PPT-U3* region in *ALVE* as shown in [Figure 5](#pone-0001731-g005){ref-type="fig"}. We found two variation sites in the two lines. One variation located in the *PPT* site changed from guanine (G[G]{.ul}GAGGGGG) in line 6~3~ to adenine (G[A]{.ul}GAGGGGG) in line 7~2~, and another variation mutated from thymidine (T) in line 6~3~ to cytosine (C) in line 7~2~. Based on the distinct feature for *ALVE* in the two lines, it shows that the sequences of the *PPT* site for *ALVE1* and *ALVE3* are G[G]{.ul}GAGGGGG (upper panel in [Figure 5](#pone-0001731-g005){ref-type="fig"})~,~ and that of the *PPT* for *ALVE2* is G[A]{.ul}GAGGGGG (lower panel in [Figure 5](#pone-0001731-g005){ref-type="fig"}).

![DNA sequencing of *PPT* region and partial *U3* region of 3′ *LTR* in *ALVE* between line 6~3~ and line 7~2~.\
Brown box shows the *PPT* region. Brown arrow shows one variation located on *PPT* region changed from G in line 6~3~ to A in line 7~2~. Black arrow shows another variation located in U3 region of 3′ *LTR* changed from T in line 6~3~ to C in line 7~2~. *n* = 11 for each line.](pone.0001731.g005){#pone-0001731-g005}

DNA methylation analysis of *ALVEs* region 2 in inbred lines and recombinant congenic strains {#s2d}
---------------------------------------------------------------------------------------------

Due to the importance of *PPT* site in *ALVEs* region 2, the quantitative measurements of methylation level in the region 2 enable monitoring of epigenetic inheritance or non-inheritance of parental methylation patterns of *ALVEs* and help us to uncover the inner mechanisms between *ALVEs* and susceptibility or resistance of neoplastic diseases in the unique population. There are 19 recombinant congenic strains (RCSs) established by a cross between the two inbred line 7~2~ and line 6~3~. The F~1~ was then consecutively backcrossed to the background line 6~3~ twice. After more than 13 generations of sib-matings within strain, each RCS is expected to contain random 7/8 background line 6~3~ and 1/8 donor line 7~2~ genome. We measured the methylation status of the *ALVE*-region 2 in blood in the two parental lines and 6 randomly selected RCS C, F, J, L, M and T. We found that the methylation patterns can easily be categorized into two groups, as exemplified in [Figure 6A and 6B](#pone-0001731-g006){ref-type="fig"}. One of the categories is extremely similar within the six RCSs and is also similar to line 6~3~ than to line 7~2~ (*P*\<0.0001). Specifically, the methylation patterns of six RCSs can be acknowledged and were inherited from the background line 6~3~, but not from the donor line 7~2~. The similarity of the methylation patterns of region 2 between RCSs and background line 6~3~ is mainly a result of the two backcrosses to line 6~3~, and it could be a potential biomarker to predict susceptibility of neoplastic disease in chickens.

![Methylation profiles of *ALVE*-region 2 in chicken inbred lines 6~3~ and 7~2~ and six recombinant congenic strains C, F, J, L, M and T.\
A. Statistical analysis results. \*\* *P*\<0.0001. B. The methylation levels are displayed in the form of a matrix. The matrix contains the data obtained form all the samples. *n* = 5 for each line or RCS.](pone.0001731.g006){#pone-0001731-g006}

DNA methylation patterns of the *TVB* promoter region {#s2e}
-----------------------------------------------------

The tumor virus B (*TVB*) locus is an important gene encoding the cellular receptor of avian leukosis virus, different *TVB* alleles can encode different receptors permitting infection by exogenous ALVB, or ALVD and endogenous ALVE. To uncover epigenetics factors contributing to susceptibility or resistance of neoplastic disease in chickens, we examined the DNA methylation status of the *TVB* gene. [Figure 2D](#pone-0001731-g002){ref-type="fig"} shows the presentative pyrograms for three CpG sites in the promoter region of the *TVB* gene in the hypothalamus tissue of both lines. The results show that the methylation level of *TVB* promoter was significantly higher in line 7~2~ than that in line 6~3~ (*P*\<0.0001, [Figure 7](#pone-0001731-g007){ref-type="fig"}). Unlike the consensus methylation trends of the *ALVEs* regions 1 and 2 ([Figure 3A and 3B](#pone-0001731-g003){ref-type="fig"}), the promoter region of *TVB* shows tissue-specific methylation patterns ([Figure 7](#pone-0001731-g007){ref-type="fig"}) similar to the promoter region 3/4 in *ALVEs* ([Figure 3C](#pone-0001731-g003){ref-type="fig"}). As shown in [Figure 7](#pone-0001731-g007){ref-type="fig"}, CpG site 3 in the promoter region of *TVB* showed a hemimethylated pattern in the spleen, liver and hypothalamus in both lines, whereas a hypomethylated pattern was disclosed in the blood. In addition, CpG site 3 of *TVB* in blood was significantly higher in line 7~2~than in line 6~3~ (*P*\<0.05). We found some variations regarding methylation contents among the 6 RCSs, especially for CpG sites 2 and 3, although the methylation patterns of RCSs were similar to background line 6~3~ ([Figure 8](#pone-0001731-g008){ref-type="fig"}).

![Results of quantitative DNA methylation analysis of inbred lines 6~3~ and 7~2~ in promoter region of *TVB* in spleen, liver, hypothalamus and blood.\
*n* = 5 for each line. \*\**P*\<0.0001, \* *P*\<0.05.](pone.0001731.g007){#pone-0001731-g007}

![Results of quantitative DNA methylation analysis in promoter region of *TVB* in blood.\
Line 6~3~ and 7~2~ are two parental lines. C, F, J, L, M and T are six recombinant congenic strains (RCS) chicken. *n* = 5 for each line and RCS. \**P*\<0.05.](pone.0001731.g008){#pone-0001731-g008}

mRNA expression level of *TVB* {#s2f}
------------------------------

The mRNA expression level of the *TVB* gene in different tissues between the line 6~3~ and line 7~2~ was further examined with real-time quantitative PCR. The results were shown in [Figure 9A and 9B](#pone-0001731-g009){ref-type="fig"}. We found that, in general, the mRNA expression levels of the *TVB* gene were higher in the liver, spleen and hypothalamus in line 6~3~ than in line 7~2~. However, this difference between the two lines was only statistically significant in the hypothalamus (*P*\<0.05), differences were not significant in the spleen (*P* = 0.15) or the liver (*P* = 0.14) ([Figure 9B](#pone-0001731-g009){ref-type="fig"}).

![mRNA expression difference of *TVB* in line 6~3~ and line 7~2~.\
*P* values indicates the statistical significance for the differences of relative *TVB* mRNA expression levels between lines 6~3~ and 7~2~ in spleen, liver, and hypothalamus, respectively. A: RT-PCR results. B: Real-time quantitative RT-PCR analysis. *n* = 5 for each line.](pone.0001731.g009){#pone-0001731-g009}

Association analysis between mRNA expression levels and DNA methylation contents {#s2g}
--------------------------------------------------------------------------------

To further explore variation resources and clarify the association between mRNA expression and DNA methylation levels, two generalized linear models were used to quantitatively evaluate the effects of lines, tissues, and the methylation contents of *ALVEs* on the expression levels of *ALVE*s *PPT-U3* region in *ALVE* and the methylation contents of *TVB* on its expression levels. Statistical analysis revealed that the effect of chicken inbred lines on the mRNA expression levels of the *PPT-U3* region in 3′ *ALVE* was statistically significant (*P*\<0.0001) (the first model). However, the effect of tissue on the mRNA expression of the *PPT-U3* region in *ALVE* was not statistically significant (*P*\>0.05). A further analysis of the line-specific results indicated that the mRNA expression level of *PPT-U3* region in *ALVE* was significantly higher in line 6~3~ than in line 7~2~. Subsequently, we analyzed the association between mRNA expression level of the *PPT-U3* region in *ALVE* and DNA methylation level of the *ALVE* region 2 using the second model. It shows that the effect of DNA methylation level on the mRNA expression level of *PPT-U3* region in *ALVE* was statistically significant (*P*\<0.0001).

Thereafter, we explored the relationship between DNA methylation level of *TVB* and mRNA expression level. There was a negative effect of methylation levels of the *TVB* promoter region on its mRNA expression from hypothalamus (*P*\<0.05). Finally, a regression analysis was done for exploring the relationship between DNA methylation level of the region 2 in *ALVE* and RNA expression level of the *PPT-U3* region in *ALVE*. As shown in [Figure 10](#pone-0001731-g010){ref-type="fig"}, there was a higher negative relationship (R^2^ = 0.7) between them. [Figure S3A and S3B](#pone.0001731.s006){ref-type="supplementary-material"} also showed a negative relationship between mRNA expression level of *ALVE PPT-U3* region and methylation level of *ALVE*-region 1 (R^2^ = 0.7) or region 3/4 (R^2^ = 0.55). Taken together, we found that the higher the methylation levels, the lower the mRNA expression level for *PPT-U3* region of *ALVE* in all tissues (*P*\<0.0001) and for the *TVB* gene in only the hypothalamus (*P*\<0.05).

![Regression analysis of mRNA expression level of *PPT-U3* region of *ALVE* and DNA methylation contents of *ALVE* region2.](pone.0001731.g010){#pone-0001731-g010}

Discussion {#s3}
==========

In this study, we observed distinct DNA methylation patterns of avian endogenous viruses (*ALVEs*) between the two inbred chicken lines, and also analyzed the DNA methylation pattern variations of *ALVE* and *TVB* genes. To the best of our knowledge, this is the first study in chickens to elucidate the variation of DNA methylation patterns variations in *ALVEs*.

The previous studies have reported that the line 6~3~ contains *ALVE1* and *ALVE3*, while line 7~2~possesses *ALVE1* and *ALVE2* in the genome respectively [@pone.0001731-Crittenden2], [@pone.0001731-Bacon3], [@pone.0001731-Cooper1], [@pone.0001731-Bacon4]. The reports were confirmed in our study as shown in [Figure S1](#pone.0001731.s004){ref-type="supplementary-material"}. Notably, we identified a unique region in *ALVE1* (named as region5, [Figure 1](#pone-0001731-g001){ref-type="fig"}) with four CpG sites and examined methylation status of the region in blood among the inbred line 6~3~ and 7~2~ and 6 RCSs as shown in [Figure 11](#pone-0001731-g011){ref-type="fig"}. We found that both inbred lines and six RCSs have nearly the same hypermethylation patterns. Therefore, our results not only provide further evidence and strong support for the previous finding that the complete *ALVE1* exists in both lines, but also indicate that *ALVE1* in the two lines may not contribute to the unique features of resistant and susceptibility of neoplastic diseases and possess inhibitory methylation [@pone.0001731-Cooper1], [@pone.0001731-Bacon4]. Since *ALVE1* did not have methylation differences between the both lines, any DNA methylation differences in conserved *ALVE* regions between line 7~2~ and line 6~3~ must be attributed to *ALVE2* and *ALVE3*, respectively.

![The results of DNA methylation analysis in a unique region of *ALVE*1 from blood in line 7~2~, line 6~3~ and RCS C, F, J, L, M and T blood.\
*n* = 5 for each line or strain. *P*\>0.05.](pone.0001731.g011){#pone-0001731-g011}

*In vitro* and *in vivo* studies in mammals have shown that retrotransposons are generally hypermethylated in normal tissues, but are hypomethylated in malignant tissues [@pone.0001731-Davis3], [@pone.0001731-Bollati1], [@pone.0001731-Lubbert1], [@pone.0001731-Waterland2], [@pone.0001731-Conklin2], [@pone.0001731-Feinberg1], [@pone.0001731-Feinberg2]. *ALVE*s belong to LTR-retrotransposons in chicken genome. In this study, the methylation level of *ALVE* conserved regions in line 7~2~ was nearly twice to six times as high as that observed in line 6~3~, which is consistent with the hypermethylated retrotransposon frequently found in normal tissues of mammals [@pone.0001731-Davis3], [@pone.0001731-Slotkin1], [@pone.0001731-Esteller1]. The methylation variations detected in this study were large in size and probably represent a strong link between DNA hypermethylation pattern of *ALVE* and resistance to ALV in the chicken. Based on association analysis, an up-regulating effect of hypomethylation in *ALVEs* region 1 and 2 was observed on *ALVE PPT-U3* expression in line 6~3~, which was in contrast to a down-regulating effect of hypermethylation in line 7~2~. However, a directly transcriptional repression effect of *ALVEs* DNA methylation on gene expression level remains to be characterized.

Notably, the methylation pattern of *ALVE*-region 2, which possesses the primer *PPT*, could be an epigenetic biomarker and has an important potential value in prevention of chicken neoplastic disease. In our study, the similarity of the methylation pattern in *ALVE* region 2 between the RCSs and background line 6~3~ is mainly because of the two continuative backcrosses to line 6~3~. Based on sequencing analysis, we found that the 6 RCSs and background line 6~3~ have the exactly same sequences on this region without any alterations (Unpublished data). On the other hand, although the methylation patterns of 6 RCSs in this region are similar to their background line 6~3~, there are some variations in the methylation patterns among the 6 RCSs. Furthermore, we found some phenotypic variations in susceptible ALV infections among 6 RCSs (Private communication, unpublished data). The epigenetic profiles of this region in RCSs were likely to be transmitted from the line 6~3~, and they retained the parental methylation patterns after over 13 generations of sib-mating. These results suggest us to further build the association between the methylation patterns and the phenotypic variations, and explore the possibility of the region as a biomarker in resistant breeding.

The polypurine tract (*PPT*) of the long terminal repeat-retrotransposons and retroviruses is a short RNA sequence from which the second or plus-strand DNA synthesis is initiated [@pone.0001731-Rausch1]. The *PPT* sequence required for plus-strand initiation was the key step for the replication of retrotransposon and retroviruses [@pone.0001731-AtwoodMoore1]. Previous studies demonstrated that the mutation in both the 5′ and 3′ halves of the human immunodeficiency virus type 1 (HIV-1) *PPT* has an effect on virus replication and titer [@pone.0001731-McWilliams1], [@pone.0001731-Miles1]. One mutation discovered in the *PPT* of 3′ *ALVEs* in our study was involved a change from a guanine (G[G]{.ul}G) in line 6~3~ to an adenine (G[A]{.ul}G) in line 7~2~ ([Figure 5](#pone-0001731-g005){ref-type="fig"}). Further study *in vitro* is to examine the function of the mutation in the *PPT* of chicken *ALVE*s on neoplastic disease.

The *TVB* locus, a single copy located on chromosome 22, is very complex and has three alleles encoding different receptors to accommodate the viral entry of different subgroups [@pone.0001731-Smith1]. The receptors encoded by two susceptible alleles *TVB\*S1* and *TVB\*S3* support viral entries of ALVB, ALVD and ALVE subgroups. *TVB\*R* is the resistant allele and encodes no functional receptors. Previous researches found that the ALVE susceptibility between line 6~3~ and line 7~2~ should be dependent on allelic differences at the receptor *TVB* locus (line 6~3~ is susceptibility SNP *TVB*-S and line 7~2~ is resistant SNP *TVB-R*) [@pone.0001731-Bacon4], [@pone.0001731-Zhang1]. Our study showed that the methylation contents of *TVB* were moderately higher in line 7~2~ than in line 6~3~, and the mRNA expression levels were reversely lower in line 7~2~ than in line 6~3~. It is worth noting that we found a variation appeared coalescence with of resistance to ALVA and ALVB in the 6 RCSs, although they have the same susceptibility SNP *TVB*-S as their background line 6~3~ (Unpublished data). In this study, the methylation profiles of *TVB* promoter in six RCSs were much close to background line 6~3~ than to line 7~2~. However, some differences in the CpG site 2 and 3 among the six RCSs chickens were identified ([Figure 8](#pone-0001731-g008){ref-type="fig"}) and they may contribute to the varied ALVA or ALVB induced tumor incidences among the six RCSs in addition to the *TVA* genotype variations.

In conclusion, our data define the consensus CpG sites methylation patterns of the conserved *ALVE* regions in the ALV-resistant line 7~2~ and -susceptible line 6~3~ are attributed to *ALVE2* and *ALVE3*, respectively. The results disclose that the mRNA expression levels of *PPT-U3* in *ALVEs* and *TVB* gene are negatively associated with the CpG methylation status in the primer region of *ALVEs* and the promoter region of *TVB*, which suggest that the hypermethylaion profiles may contribute to ALV resistance in the chickens. The *ALVE*-region2, the *PPT* located region, could be considered as an epigenetic biomarker for resistant breeding against neoplastic disease in chicken.

Materials and Methods {#s4}
=====================

Animal Samples {#s4a}
--------------

All samples were collected from highly inbred chickens of lines 6~3~, 7~2~, and recombinant congenic strains (RCS). Five 15 month old females from chicken line 6~3~ and line 7~2~, and five 12 month old females from line 6~3~, 7~2~ and six RCSs (C, F, J, L M and T) were tested. Heparinized blood was collected from each chicken prior to euthanasia. Then tissue samples from 15 month-olds chickens were obtained from three organs: hypothalamus, liver and spleen. Tissues were frozen in liquid nitrogen prior to storage at −80°C.

DNA extraction and bisulfite treatment {#s4b}
--------------------------------------

DNA was extracted from 20 µl blood or 3 mm^3^ tissue samples using a phenol-chloroform method. DNA concentration was measured by a spectrophotometer (Bio-Rad). 1 µg DNA of each sample was treated with bisulfite with EZ DNA Methylation Golden Kit (ZYMO Research) as the manufacture\'s protocols. Bisulfite converted DNA was eluted in 20 µl elution buffer (ZYMO Research).

PCR and pyrosequencing primers {#s4c}
------------------------------

PCR and pyrosequencing primers were designed to amplify 3∼6 CpG dinucleotides sites in each gene region, including four conserved regions among *ALVE1*, *ALVE2* and *ALVE3*, a unique region in *ALVE1* [@pone.0001731-Johnson1], and one promoter region of *TVB* gene ([Figure 1](#pone-0001731-g001){ref-type="fig"} and [Table 1](#pone-0001731-t001){ref-type="table"}). Forward and reverse primers used in PCR and the sequencing primers used in pyrosequencing methylation assays were designed with PSQ Assay Design software (Biotage, Swedan). To save time and cost, a biotin labeled universal primer (5′-GGGACACCGCTGATCGTTTA-3′) was used in the PCR assays [@pone.0001731-Colella1]. The 5′ end of each reverse primer was tailed with the same sequence as the universal primer ([Table 1](#pone-0001731-t001){ref-type="table"}).
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###### PCR and pyrosequencing primers and assays for each gene.

![](pone.0001731.t001){#pone-0001731-t001-1}

  Gene[A](#nt101){ref-type="table-fn"}      Assay      CpG sites[B](#nt102){ref-type="table-fn"}                                    Primers                                                     Sequence[C](#nt103){ref-type="table-fn"}
  -------------------------------------- ------------ ------------------------------------------- --------------------------------------------------------------------------- -----------------------------------------------------------------------------
                                            6: 882                        892                                                       Forward                                                             5′-TTAGGGGGAGGGAGGGTTT-3′
  *ALVE*-region1                             905                          911                                                       Reverse                                                5′-GGGACACCGCTGATCGTTTA CCATCTTCACATCTCGCTACACAA-3′
                                             914                          919                                                     Sequencing                                                            5′-GAGGGTTTTTTTTTTAGGT-3′
                                                                         Assay                     5′-T**Y**GGAGTGTA T**Y**GAGAAATT AGTAA**Y**GGAG **Y**GG**Y**GAAT**Y**G-3′  
                                           5: 7171                       7178                                                       Forward                                                         5′-GTATATGGGTGGTGGTATGAAATTTG-3′
  *ALVE*-region2                             7186                        7194                                                       Reverse                                                 5′-GGGACACCGCTGATCGTTTA TTCCCCCTCCCTATACAAAAAC-3′
                                             7196                                                                                 Sequencing                                                           5′-GAGGGGATTATAGTATGTAT-3′
                                                                         Assay                       5′-AGG**Y**GAAAGG **Y**GGGGTTT**Y**G GTTGTA**Y**G**Y**G GTTAGGAGTT-3′    
                                            3′ LTR                       5′LTR                                                      Forward                                                          5′-TGGYGATTAGATAAGGAAGGAATG-3′
  *ALVE* -region3/4                        4: 7359                      4: 108                                                      Reverse                                               5′-GGGACACCGCTGATCGTTTA TATCCATCTACCCAAATACACACCA-3′
                                             7375                         124                                                     Sequencing                                                           5′-YGATTAGATAAGGAAGGAAT-3′
                                             7381                         130                                                        Assay                                     5′-GA**Y**GTAAGGA TATATGGG**Y**G TAGA**Y**GAAGT TATGTA**Y**GATTATATAAGTT-3′
                                             7393                         142                                                                                                 
                                           4: 3793                                                                                  Forward                                                          5′-AGGCGTTTATTGTTTGGTTAGAAG-3′
  *ALVE* -region5                            3795                                                                                   Reverse                                                5′-GGGACACCGCTGATCGTTTA CAAAAAAATATCAACCTCCTTACC-3′
                                             3800                                                                                 Sequencing                                                           5′-TTATTTTTTTGATTATTAAG-3′
                                             3808                                                                                    Assay                                       5′-TTA**Y**G**Y**GTTT **Y**GGTAGTG**Y**G AATTTTTGGT AAGGAGGTTG ATAT-3′
                                                                        Forward                                         5′-ATGTGTAGGTTATGGGAAGGGTAT-3′                        
  *TVB*                                   3: 1282407                                                                                Reverse                                                5′-GGGACACCGCTGATCGTTTA AAAACTAAACTACTCCCACCATTT-3′
                                           1282435                                                                                Sequencing                                                             5′-GGTTATGGGAAGGGTA-3′
                                           1282444                                                                                   Assay                                         5′-TAA**Y**GTGGTT ATGGTGTTTT TGTTTGGTTG T**Y**GTTGTTTA **Y**GTA-3′
                                                                       Universal                                  5′-/Biotin labeled/GGGACACCGCTGATCGTTTA-3′                  

*ALVE*-region1, 2, 3/4: based on the conserved DNA sequence between *ALVE1* (AY013303) and *ALVE3* (AY013304). The relative product of *ALVE* region1 is p19 matrix protein of *gag* gene. *ALVE* region2 is the consensus sequence of oncogene Direction Repeat Sequence (DRS). *ALVE* region3/4 is the conserved DNA sequence-U3 region, which located in 5′*LTR* and 3′*LTR* of *ALVE*s. *ALVE* region5: based on the unique DNA sequence (reverse transcriptase alpha subunit) in *ALVE1* (AY013303,[@pone.0001731-Johnson1]. *TVB*: based on the UCSC DNA sequence (May 2006, Chr22) that BLAT from *TVB* cDNA sequence (AF161712), it is on the promoter region of *TVB*.

The CpG site numbers and positions.

Y and R stand for C/T and G/A, respectively. Bold Y is the CpG sites assayed in each region.

Hot start PCR amplification {#s4d}
---------------------------

The hot start PCR was carried out in 30 µl solution for ALVE and TVB genes: 1.5 µl bisulfite treated DNA (1∶5 dilution), 1×PCR buffer, 0.2 mM dNTPs, 0.5 µM forward primer, 0.05 µM reverse primer with universal tail, 0.45 µM biotin labeled universal primer, and 0.75 U Qiagen\'s Hotstar Taq DNA polymerase. PCR cycling conditions were 95°C for 15 min, followed by 50 cycles at 94°C for 30 sec, 50∼60°C for 45 sec, and 72°C for 45 sec, and a final incubation at 72°C for 10 min. PCR product quality verification was defined using 1.5% agarose gels with ethidium bromide.

Pyrosequencing methylation analysis {#s4e}
-----------------------------------

Based on the concentration of the PCR product, 10∼25 µl PCR product was used for each pyrosequencing reaction. Pyrosequencing methylation analysis was carried out using the Pyro Q-CpG system (PyroMark ID, Biotage, Sweden) according to the manufacture\'s protocol. In brief, the PCR product was bound to Streptavidin coated Sepharose beads (GE Healthcare Bio-sciences AB, Sweden). The Sepharose beads containing the immobilized PCR product were purified in 70% ethanol for 5 sec, denatured in Denature buffer (Biotage) for 5 sec, and washed with Washing buffer (Biotage) for 10 sec using the pyrosequencing Vacuum Prep Tool (Biotage). Then, 0.5 µM sequence primer was annealed to the purified single-stranded PCR product and pyrosequencing was carried out using the Pyro Q-CpG system. The level of methylation was expressed for each cytosine locus on CpG sites as the percentage of ^m^C/(^m^C+C) ([Figure 2](#pone-0001731-g002){ref-type="fig"}, ^m^C is methylated cytosine, C is unmethylated cytosine). Non-CpG cytosine residues were used as controls to verify bisulfite conversion.

Real-time RT-PCR {#s4f}
----------------

Total RNA of 5 individuals from each line was extracted from liver, spleen and hypothalamus using an RNeasy Midi kit (Qiagen). The first strand cDNA was synthesized from total RNA using SuperScript™ III Reverse Transcriptase (Invitrogen). Samples were then analyzed by real time RT-PCR using an iCycler iQ PCR system (Bio-Rad). The real time RT-PCR reactions were performed in a final volume of 20 µl with a QuantiTect SYBR Green PCR Kit (Qiagen) according to the manufacture\'s instructions. The mRNA expression of *PPT* (Polypurine tract) with *U3* region (termed as *PPT-U3*) on 3′ *LTR* of *ALVE* and *TVB* was normalized against the housekeeping gene *GAPDH* (glyceraldehyde-3-phosphate dehydrogenase) cDNA in the corresponding samples.

Statistical analysis {#s4g}
--------------------

Statistical analyses were conducted with the SAS 9.1.3 package. Point-wise comparison was carried out to analyze the difference of methylation contents between two lines at different CpG sites. Student\'s *t* test was done for analyzing mRNA expression levels of the *PPT-U3* region in 3′-*ALVE* between line 6~3~ and line 7~2~. The GLM (generalized linear model) program was used to analyze the association between the RNA expression levels and lines, tissues or DNA methylation levels. The first model is: *y* = *μ*+*l*+*t*+*e*, where *y* is the RNA expression level of *PPT-U3* region in 3′*LTR* of *ALVE*, *µ* is the overall mean, *l* is the class of line (Line 6~3~ and Line 7~2~), *t* is the type of tissue (liver, spleen or hypothalamus), and *e* is residual effect. The second model is: y = *μ*+m+t+e, where *y*, *µ* , *t* and *e* have the same meaning as that in the first model, and *m* is the DNA methylation level of *ALVE* region 2 or the promoter region in *TVB*, respectively. We also did the regression analysis of DNA methylation contents of *ALVE* region 1, 2 and 3/4 on mRNA expression level of the *PPT-U3* region in *ALVEs*.

Supporting Information {#s5}
======================

###### 

The methylation percentage (%) of ALVE-region1 in line 6~3~ and line 7~2~

(0.03 MB TIF)

###### 

Click here for additional data file.
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The methylation percentage (%) of ALVE-region2 in line 6~3~ and line 7~2~

(0.03 MB DOC)

###### 

Click here for additional data file.

###### 

The methylation percentage (%) of ALVE-region3/4 in line 6~3~ and line 7~2~

(0.03 MB DOC)

###### 

Click here for additional data file.

###### 

PCR diagnostics for *ALVE1*, *ALVE2* and *ALVE3* in line 6~3~ and line 7~2~. *n* = 3 for each line. L63: line 6~3~; L72: line 7~2~. M: 100 bp markers. "-" is negative control. A. Left panel of Marker lane shows that line 6~3~ and line 7~2~ are all positive *ALVE1* birds. Right panel of Marker lane shows that line 7~2~ is *ALVE2* positive birds, however, line 6~3~ is *ALVE2* negative birds. B. Line 6~3~ is *ALVE3* positive birds, and line 7~2~ is *ALVE3* negative birds.

(0.99 MB DOC)

###### 

Click here for additional data file.

###### 

Validation of pyrosequencing results by bisulfite cloning and sequencing methods. TA Cloning Kit (Invitrogen Inc.) was used in cloning. The sequencing was done by ABI 3730. Black dots show methylated CpG sites, while open dots show unmethylated CpG sites. The same bisulfite treated spleen DNA from line 7~2~ (A) and line 6~3~ (B) was tested with cloning and sequencing (right panel) and pyrosequencing (left panel).

(2.12 MB TIF)

###### 

Click here for additional data file.

###### 

Regression analysis of mRNA expression level of *PPT-U3* region of *ALVE* and DNA methylation contents of *ALVE* region1 ([Figure 3A](#pone-0001731-g003){ref-type="fig"}) and *ALVE* region3/4 ([Figure 3B](#pone-0001731-g003){ref-type="fig"}).

(0.87 MB TIF)

###### 

Click here for additional data file.
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